Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (201-210 of 269) with videos related to

Pageof 27
Sort By:
Lancet (London, England)|November 24, 2024
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Geert D'Haens, Vipul Jairath, et al.
Gastroenterology|July 24, 2019
Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's DiseasePieter Hindryckx, Vipul Jairath, Guangyong Zou, et al.
Gastroenterology|March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flavio Steinwurz, et al.
Lancet (London, England)|September 7, 2015
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trialReena Khanna, Brian Bressler, Barrett G Levesque, et al.
Gastroenterology|November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
The American Journal of Gastroenterology|January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
Inflammatory Bowel Diseases|September 18, 2010
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's diseaseC Janneke van der Woude, Pieter Stokkers, Ad A van Bodegraven, et al.
Inflammatory Bowel Diseases|October 24, 2019
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's DiseaseJames D Lewis, Paul Rutgeerts, Brian G Feagan, et al.
World Journal of Gastroenterology|January 2, 2018
Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel diseaseLieke M Spekhorst, Bas Oldenburg, Ad A van Bodegraven, et al.
Inflammatory Bowel Diseases|January 24, 2018
Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance EnterographyVipul Jairath, Ingrid Ordas, Guangyong Zou, et al.
Pageof 27

Showing results (201-210 of 269) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|November 24, 2024
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Geert D'Haens, Vipul Jairath, et al.
Gastroenterology|July 24, 2019
Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's DiseasePieter Hindryckx, Vipul Jairath, Guangyong Zou, et al.
Gastroenterology|March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flavio Steinwurz, et al.
Lancet (London, England)|September 7, 2015
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trialReena Khanna, Brian Bressler, Barrett G Levesque, et al.
Gastroenterology|November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
The American Journal of Gastroenterology|January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
Inflammatory Bowel Diseases|September 18, 2010
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's diseaseC Janneke van der Woude, Pieter Stokkers, Ad A van Bodegraven, et al.
Inflammatory Bowel Diseases|October 24, 2019
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's DiseaseJames D Lewis, Paul Rutgeerts, Brian G Feagan, et al.
World Journal of Gastroenterology|January 2, 2018
Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel diseaseLieke M Spekhorst, Bas Oldenburg, Ad A van Bodegraven, et al.
Inflammatory Bowel Diseases|January 24, 2018
Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance EnterographyVipul Jairath, Ingrid Ordas, Guangyong Zou, et al.
Pageof 27